Envisagenics is a biotechnology company using artificial intelligence and RNA sequencing to discover and develop therapeutics that arrest RNA splicing errors in cancer and genetic diseases. The company is headquartered in New York City, New York and was founded in 2014 by Maria Luisa Pineda and Martin Akerman.
Funding
Seed round
On November 23, 2017 Envisgenics closed their seed funding round with $2.35 million in funding. Dynamk Capital lead the seed funding round, but several other investors participated, including: Third Kind Venture Capital, SV Angel, New York State, Dolby Family Ventures, and Cosine.
Timeline
People
Adrian Krainer
Professor & Program Chair
Maria Luisa Pineda
Co-Founder & CEO
Martin Akerman
Co-Founder & CTO
Michael Schatz
Associate Research Professor
Michael Zhang
Professor & Director
Omar Abdel-Wahab
Hematologic Oncologist
Further reading
Microsoft Announces Winners of AI Startup Competition
Meir Orbach
Web
Platform Targeting Genetic Cause of SMA and Like Diseases Supported by $1.5M NIH Grant
Carolina Henriques
Web
Thiel's Breakout Labs backs Envisagenics
Gina Hall
Web
Documentaries, videos and podcasts
Auto-extract from URL...
Companies
References
Envisagenics
Company
New York
United States
New York City
Martin Akerman
Biotechnology
Drug discovery
Artificial intelligence (AI)
Machine learning
Deep learning
DNA sequencing
Contributors
- 1
Dawson Sewell
Seeking to explain science and technology through simple writing. - 2
Melanie Manipula
Researcher, writer and a former librarian - 3
Jude Gomila
Founder and CEO of Golden, Entrepreneur. Previously Co Founder of Heyzap. Investor in 100+ companies. Cantabrigian (Gonville and Caius). - 4
Carla Faraguna
Golden People and Operations.
